Thyroid Adenocarcinoma

Thyroid adenocarcinoma is a malignant neoplasm arising from the follicular epithelial cells of the thyroid gland. It is the most common thyroid malignancy in dogs and is rare in cats, where benign adenomas predominate. In dogs, thyroid adenocarcinomas are typically unilateral or bilateral, often invasive into surrounding cervical structures (trachea, esophagus, carotid sheath, recurrent laryngeal nerve) and metastasize to regional lymph nodes and lungs. In cats, malignant thyroid tumors are uncommon, but when they occur, they are usually adenocarcinomas with a higher metastatic potential. The tumor disrupts normal thyroid hormone production, leading to clinical signs of hyperthyroidism (in cats) or hypothyroidism (in dogs, if bilateral destruction occurs), although many dogs are euthyroid. The disease is classified by histologic grade (well-differentiated, moderately differentiated, poorly differentiated) and clinical stage (TNM system).

The exact etiology of thyroid adenocarcinoma is largely unknown, but several factors are implicated. Chronic thyroid-stimulating hormone (TSH) stimulation, as seen in chronic hypothyroidism, may promote follicular cell hyperplasia and neoplasia. Genetic mutations, such as activation of the RAS/RAF/MEK/ERK pathway and mutations in the PI3K/AKT pathway, have been identified in human thyroid cancer and are suspected in canine and feline cases. Exposure to ionizing radiation, particularly in cats that received radioiodine treatment for hyperthyroidism, has been associated with the development of malignant transformation. Chronic inflammation (thyroiditis) and goitrogens in the diet may also contribute. No specific viral or bacterial etiology has been identified.

Thyroid adenocarcinoma is primarily a disease of middle-aged to older dogs, with a median age of 9-10 years. Certain breeds are predisposed, including Beagles, Boxers, Golden Retrievers, and Siberian Huskies. No sex predilection is consistently reported. In cats, malignant thyroid tumors are rare, accounting for less than 5% of feline thyroid tumors; they occur in older cats (median age 12-15 years) with no breed predilection. The incidence in dogs is estimated at 1-2% of all canine tumors. Geographic variation is not well-documented, but iodine-deficient regions may have higher rates.

Thyroid adenocarcinoma arises from follicular cells and disrupts normal thyroid hormone synthesis and secretion. The tumor may produce excessive thyroid hormones (T3 and T4), leading to hyperthyroidism, particularly in cats. In dogs, hyperthyroidism is rare; more commonly, the tumor causes hypothyroidism due to destruction of normal thyroid tissue. The malignant cells invade locally, often encasing the trachea, esophagus, and major vessels, causing mechanical obstruction and dysfunction. Metastasis occurs via lymphatic and hematogenous routes, most commonly to regional lymph nodes (mandibular, retropharyngeal) and lungs. The tumor may also invade the vena cava and heart. Paraneoplastic syndromes, such as hypercalcemia, have been reported. The molecular mechanisms involve dysregulation of cell cycle, apoptosis, and angiogenesis, driven by mutations in oncogenes and tumor suppressor genes.

Intrinsic factors include advanced age, breed predisposition (Beagles, Boxers, Golden Retrievers), and possibly genetic susceptibility. Extrinsic factors include chronic TSH stimulation from hypothyroidism, exposure to radiation (especially in cats treated with radioiodine), and dietary goitrogens (e.g., brassica vegetables) in iodine-deficient regions. Concurrent endocrine disorders, such as hyperadrenocorticism, may also increase risk. Immunosuppression and chronic inflammation are less well-defined risk factors.

Clinical signs vary depending on the functional status of the tumor and the degree of local invasion. In dogs, a palpable cervical mass is the most common finding, often noted incidentally. Signs related to local invasion include dysphagia, dysphonia, coughing, dyspnea, and Horner's syndrome (if sympathetic trunk is involved). Hyperthyroidism signs (weight loss, polyphagia, tachycardia, hyperactivity) are rare in dogs but may occur. Hypothyroidism signs (lethargy, weight gain, alopecia, bradycardia) can develop if the tumor destroys normal thyroid tissue. In cats, signs are predominantly those of hyperthyroidism: weight loss despite polyphagia, vomiting, diarrhea, hyperactivity, and tachycardia. A palpable cervical mass may be present. In advanced cases, signs of metastasis (e.g., respiratory distress from lung metastases) may dominate.

Differential diagnoses for a cervical mass in dogs and cats include: (1) Thyroid adenoma (benign, non-invasive, no metastasis), (2) Ectopic thyroid tissue (rare, may be functional), (3) Salivary gland neoplasia (e.g., adenocarcinoma), (4) Lymphadenopathy (reactive or neoplastic, e.g., lymphoma), (5) Branchial cyst (fluid-filled, benign), (6) Carotid body tumor (chemodectoma, often at bifurcation), (7) Abscess (painful, febrile, responds to antibiotics), (8) Granuloma (fungal or foreign body), (9) Other soft tissue sarcomas (e.g., fibrosarcoma). Key distinguishing features: thyroid adenomas are usually small, well-circumscribed, and non-invasive; adenocarcinomas are invasive and may cause clinical signs of thyroid dysfunction. Imaging (ultrasound, CT) and cytology/histopathology are essential for definitive diagnosis.

1. History and physical examination: Palpate the cervical region for a mass; assess for signs of thyroid dysfunction. 2. Baseline blood work: CBC, serum biochemistry, urinalysis, and thyroid hormone levels (T4, fT4, TSH). 3. Thoracic radiographs: Evaluate for pulmonary metastases. 4. Cervical ultrasound: Assess the thyroid gland, mass characteristics (echogenicity, vascularity), and local lymph nodes. 5. Fine-needle aspiration (FNA) of the mass and lymph nodes for cytology. 6. Advanced imaging (CT or MRI) if surgical planning is needed, to assess invasion into surrounding structures. 7. Histopathology via incisional or excisional biopsy for definitive diagnosis and grading. 8. If hyperthyroidism is present, consider scintigraphy (technetium-99m pertechnetate) to assess functional status and metastatic spread.

Hematology: Often unremarkable; may show mild anemia of chronic disease. Serum biochemistry: Hypercalcemia may be present (paraneoplastic). Liver enzymes (ALT, ALP) may be elevated in hyperthyroid cats. Thyroid hormone assays: In dogs, T4 and fT4 may be low, normal, or high; TSH may be elevated in hypothyroid states. In cats, T4 is typically elevated. Urinalysis: Usually normal; specific gravity may be low if hypercalcemia. Blood gas analysis: Not typically indicated. Biomarkers: Thyroglobulin levels may be elevated. Serology/PCR: Not applicable.

Radiography: Thoracic radiographs may reveal pulmonary metastases (nodules). Cervical radiographs may show a soft tissue mass with possible tracheal deviation. Ultrasonography: Thyroid mass appears as a hypoechoic, heterogeneous mass with irregular borders; Doppler may show increased vascularity. Enlarged regional lymph nodes may be visualized. CT: Provides detailed assessment of local invasion (trachea, esophagus, vessels) and is essential for surgical planning. MRI: Superior soft tissue contrast, useful for evaluating invasion into the spinal canal or mediastinum. Scintigraphy: Functional imaging with pertechnetate shows increased uptake in thyroid tissue, including metastases.

Cytology (FNA): May show clusters of follicular cells with anisocytosis, anisokaryosis, and prominent nucleoli. However, cytology cannot reliably distinguish adenoma from adenocarcinoma. Histopathology: Definitive diagnosis. Features include capsular invasion, vascular invasion, and cellular atypia. Tumors are graded as well-differentiated (minimal atypia, rare mitoses), moderately differentiated, or poorly differentiated (marked atypia, high mitotic rate, necrosis). Immunohistochemistry for thyroglobulin and thyroid transcription factor-1 (TTF-1) can confirm thyroid origin.

Treatment depends on the functional status, tumor stage, and presence of metastasis. For non-metastatic, resectable tumors, surgical excision (thyroidectomy) is the treatment of choice. In dogs, bilateral thyroidectomy may be necessary, but this can result in hypothyroidism requiring lifelong thyroid hormone supplementation. For invasive or non-resectable tumors, radiation therapy (external beam or radioiodine) is recommended. Radioiodine (I-131) is effective for hyperthyroid cats and dogs with functional tumors. Chemotherapy (e.g., doxorubicin, cisplatin) may be used for metastatic disease, but response rates are variable. Supportive care includes management of hyperthyroidism (methimazole, beta-blockers) or hypothyroidism (levothyroxine). Pain management and nutritional support are important.

Prognosis is variable. In dogs, median survival time for thyroid adenocarcinoma is approximately 2-3 years with surgical excision if the tumor is well-differentiated and completely resected. Poorly differentiated tumors and those with vascular invasion have a worse prognosis (median survival <1 year). Metastasis at diagnosis is a negative prognostic indicator. In cats, malignant thyroid tumors are rare but aggressive; median survival is shorter, often <1 year. Hyperthyroid cats with adenocarcinoma may respond to radioiodine, but metastatic disease carries a poor prognosis.

Post-treatment monitoring includes: Recheck thyroid hormone levels (T4, TSH) every 3-6 months to assess for hypothyroidism or hyperthyroidism. Thoracic radiographs every 3-6 months for the first 2 years to monitor for pulmonary metastases. Cervical ultrasound every 6-12 months to assess for local recurrence. If on levothyroxine, adjust dose based on T4 levels. If on methimazole, monitor for side effects (e.g., hepatotoxicity, blood dyscrasias). Long-term management may require ongoing endocrine support.

Pearls: Always evaluate thyroid hormone status in any dog with a cervical mass, as hypothyroidism may be present. Use CT for surgical planning to assess invasion. In cats, a palpable thyroid nodule with hyperthyroidism is usually benign, but malignant transformation should be suspected if the mass is large, invasive, or if there is no response to methimazole. Pitfalls: Do not rely solely on cytology to differentiate adenoma from adenocarcinoma; histopathology is essential. Avoid fine-needle aspiration of a suspected carotid body tumor, as it may cause hemorrhage. Do not overlook metastatic disease; always perform thoracic radiographs.

For hyperthyroidism: Methimazole (Tapazole) 2.5-5 mg/cat PO q12h, or 10-15 mg/dog PO q12h, adjust to maintain T4 in normal range. Beta-blockers (e.g., propranolol 2.5-5 mg/cat PO q8h) for tachycardia. For hypothyroidism: Levothyroxine (Soloxine) 0.1-0.2 mg/dog PO q12h, or 0.05-0.1 mg/cat PO q12h, adjust based on T4 levels. For chemotherapy: Doxorubicin 30 mg/m² IV q3 weeks (dogs), or cisplatin 60-70 mg/m² IV q3 weeks (dogs, with saline diuresis). For pain: NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h) or opioids (e.g., tramadol 2-5 mg/kg PO q8h). Always adjust doses for renal/hepatic impairment and monitor for drug interactions.

Key studies: A retrospective study by Liptak et al. (2004) reported median survival of 36 months in dogs with thyroid adenocarcinoma treated with surgery alone. Another study by Theon et al. (2000) showed that radiation therapy improved local control in dogs with non-resectable tumors. In cats, a study by Naan et al. (2006) found that malignant thyroid tumors have a high metastatic rate and poor prognosis. ACVIM consensus guidelines on thyroid disease recommend histopathologic grading and staging for prognosis. Plumb's Veterinary Drug Handbook provides current dosing guidelines for methimazole and levothyroxine.